FIGS, Inc. FIGS
FIGS is a fading pandemic winner whose founders exaggerated revenue 82% and TAM 135%; at ~4x sales versus 1.2x DTC peers, Spruce Point sees 45%-60% downside to $4.40-$6.05.
Thesis
FIGS, a direct-to-consumer healthcare-apparel brand that IPO'd in 2021 after COVID-era tailwinds, is built on an origin story Spruce Point argues is largely fiction. Co-founder Heather Hasson misrepresented a seven-year Italian handbag career records show never meaningfully existed, and management has a pattern of inflating metrics — historical revenue overstated roughly 82%, gross margins by 2,040 basis points, and US TAM by 135% to $12 billion versus Spruce Point's $5.1 billion estimate. Finance-department turnover has been extreme, inventory days have ballooned to 324 (triple the DTC peer average), and an SPI lawsuit alleges false antimicrobial claims not permitted under SILVADUR's own brand guidelines. With FIGS still trading at ~4x 2022E revenue versus a 1.2x DTC-peer average, Spruce Point models 45%-60% downside to a $4.40-$6.05 target.
SCQA
FIGS is a 2021 IPO DTC retailer of medical scrubs that rode COVID-era tailwinds from $18M revenue in 2017 to $419M in 2021, branding itself a premium healthcare-apparel disruptor with 'structurally advantaged' margins.
Spruce Point documents a pattern of exaggeration: fabricated origin story, revenue inflated 82% and gross margins by 2,040 bps, TAM overstated 135%, ballooning inventory, finance-team turnover, and an SPI lawsuit alleging false antimicrobial advertising.
Short FIGS. Spruce Point issues a Strong Sell Opinion and applies a 1.5x-2.0x 2022E revenue multiple aligned with DTC peer comparables, rather than the ~4x premium the market currently awards.
Target price of $4.40-$6.05 per share against the $11.04 quote, representing 45%-60% downside as growth normalizes, inventory unwinds, and the market re-rates FIGS to peer multiples.
The three reasons
- 1
Historical revenue inflated ~82%, gross margins overstated 2,040 bps, US TAM exaggerated 135%
- 2
No sustainable competitive advantage as premium-scrubs landscape is now crowded with DTC rivals
- 3
Trades at ~4x 2022E revenue vs 1.2x DTC-peer average; 45%-60% downside to $4.40-$6.05
Primary demands
- Sell FIGS shares — Strong Sell Opinion
- Re-rate FIGS to DTC peer multiples (1.5x-2.0x 2022E revenue) instead of ~4x premium
- Scrutinize co-founders' origin story, exaggerated metrics, and antimicrobial product claims
- Replace unseasoned finance leadership and address governance lapses on the audit committee
KPIs cited
Pattern membership
Precedents cited
- Oatly (OTLY) — prior Spruce Point short, shares declined 88%
- WD-40 (WDFC) — prior Spruce Point short on inventory accounting
- Church & Dwight (CHD) — prior Spruce Point short on FLAWLESS acquisition
Composition what's on the 113 slides
Slide gallery ·
Notes
113-page forensic short report titled 'A Forensic Examination of FIGS' Leaf'. Cover uses the 'This might hurt a little' syringe metaphor — memorable genre opener. Spruce Point leads with its own track-record slide (Oatly, WD-40, Church & Dwight) as credibility priming, a recurring short-seller pattern. Heavy reliance on the SPI v. FIGS lawsuit record (Case 2:19-cv-02286) as evidentiary scaffolding for the false-advertising angle on SILVADUR antimicrobial claims. No named individual author — firm-level signature only. Campaign phase set to initial_thesis as this appears to be Spruce Point's first public short report on FIGS. stake_disclosed_pct left null: disclaimer states SPCM 'has a short position' but does not quantify it as an ownership percentage. Final 'Sell The Truth' slide (p.95) turns a Spear quote back on her as a closing rhetorical punch.